cover image: Mycophenolate mofetil tablets for uveitis

Premium

20.500.12592/vthz89

Mycophenolate mofetil tablets for uveitis

25 May 2011

TITLE: Mycophenolate Mofetil Tablets for Uveitis: A Review of the Comparative Clinical and Cost-Effectiveness DATE: 25 May 2011 CONTEXT AND POLICY ISSUES Uveitis is an inflammation within the eye from the uveal tract, which is made up of three structures – the iris, the ciliary body, and the choroid.1-3 Inflammation of these structures may result in symptoms such as eye pain, red eye, light sensi [...] Recommended dosing of MMF in uveitis ranges from 500mg twice per day to 1500 mg twice per day.1,5 Based on the recommended dosing of MMF in uveitis and on its price in Canadian provincial drug formularies that reimburse this drug6,7, the daily cost of MMF in uveitis ranges from $8.24 to $24.75, making it more expensive than other immunosuppressants listed in Canadian formularies.6-9 Disclaimer:. [...] The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. [...] The present review was undertaken to summarize the evidence for the comparative clinical effectiveness and cost-effectiveness of MMF in uveitis, with the aim of informing decisions regarding the use of this treatment. [...] In contrast, the proportion of patients in whom the dose of antimetabolite therapy was increased was higher in the methotrexate group (64%) compared with azathioprine (32%) and MMF (36%), (p<0.001).
health cost-benefit analysis research systematic reviews drugs immunology medical research medicine health care therapy technology assessment, biomedical clinical trial clinical medicine randomized controlled trials healthcare policy health treatment health sciences government health care controlled trials medical drugs medical specialties diseases and conditions centre for reviews and dissemination cochrane mycophenolic acid mycophenolate mofetil cellcept azathiorprine azathioprine uveitis immunosuppressive drug infliximab
Pages
10
Published in
Canada

Related Topics

All